Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AlbuCAT: Albumin for Hypervolemic Hyponatremia in Cirrhosis
NCT03941405Phase 2Completed
- Sponsor
- Fundació Clínic per a la Recerca Biomèdica
- Start
- Feb 2020
- Primary completion
- Dec 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of albumin (human) in hyponatremia (hypervolemic) (2 arms), sponsored by Fundació Clínic per a la Recerca Biomèdica. Primary endpoint: Resolution of hyponatremia at 10 days. Started Feb 2020; status: completed.
02
Drugs
albumin (human)
03
Conditions
hyponatremia (hypervolemic)
Beyond the preview
Go deeper on NCT03941405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03941405.